Reemergence of PML in natalizumab-treated patients--new cases, same concerns.
Major
Eugene O
EO
Laboratory of Molecular Medicine and Neuroscience, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA.
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018952:Antigens, CD34 / Q000097:blood; D015415:Biomarkers / Q000097:blood; D004279:DNA, Viral / Q000097:blood; D006801:Humans; D039441:Integrin alpha4 / Q000276:immunology*; D007577:JC Virus / Q000187:drug effects / Q000302:isolation & purification / Q000502:physiology; D007968:Leukoencephalopathy, Progressive Multifocal / Q000139:chemically induced*; D009103:Multiple Sclerosis / Q000150:complications / Q000188:drug therapy*; D000069442:Natalizumab; D014556:Urine / Q000821:virology; D014775:Virus Activation / Q000187:drug effects*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018952:Antigens, CD34; D015415:Biomarkers; D004279:DNA, Viral; D000069442:Natalizumab; D039441:Integrin alpha4